Inventage Lab will be attending BIO International Convention 2026, taking place June 22–25, 2026 in San Diego, California, US.
BIO International Convention is the world's largest biotechnology partnering event, bringing together 10,000+ industry leaders from 65+ countries and facilitating tens of thousands of one-on-one partnering meetings. The convention serves as the premier global dealmaking platform where leading pharma, biotech, and investment organizations converge to explore licensing, co-development, and strategic collaboration opportunities.
Inventage Lab is a publicly listed, clinical-stage biotech headquartered in South Korea, developing proprietary microfluidic-based drug delivery platforms. Our portfolio includes DrugFluidic®, a platform for long-acting injectable (LAI) formulations of small molecules and peptides; BioFluidic™, designed to optimize subcutaneous delivery of antibodies and protein therapeutics; and GeneFluidic®, an LNP-based delivery platform for nucleic acid therapeutics. Each platform is engineered to overcome the limitations of conventional formulations and to maximize the pipeline value of our global partners.
At BIO International 2026, Inventage Lab will be exhibiting at Booth #4913. Visit us to explore co-development, licensing, and CDMO partnership opportunities across oncology, metabolic disease, neurology, and CNS indications, or schedule a one-on-one partnering meeting in advance. We welcome inquiries from pharma and biotech companies seeking differentiated formulation technologies to advance their global pipelines.
